2020 Year in Review - Lung Cancer

Pralsetinib and Selpercatinib for NSCLC Patients with RET Gene Fusions

2020 Year in Review - Lung Cancer - Lung Cancer

Lorlatinib Improves Outcomes Over Crizotinib in First-Line Setting of ALK-Positive NSCLC

2020 Year in Review - Lung Cancer - Lung Cancer

Combination Ramucirumab and Erlotinib for NSCLC with EGFR Exon 19 or Exon 21 Mutations

2020 Year in Review - Lung Cancer - Lung Cancer

Capmatinib for Patients with NSCLC with MET Exon 14 Mutation

2020 Year in Review - Lung Cancer - Lung Cancer

Anti-TIGIT Antibody Tiragolumab plus Atezolizumab in Patients with PD-L1–Selected NSCLC

2020 Year in Review - Lung Cancer - Lung Cancer

Phase 3 EMPOWER-Lung 1 Study of Cemiplimab in Advanced PD-L1–Positive NSCLC

2020 Year in Review - Lung Cancer - Lung Cancer

Updated Analysis of PFS Data from Cohort G of KEYNOTE-021 in Nonsquamous NSCLC

2020 Year in Review - Lung Cancer - Lung Cancer

Durvalumab Demonstrates Sustained Overall Survival in Unresectable Stage III NSCLC

2020 Year in Review - Lung Cancer - Lung Cancer

ADAURA Results: Osimertinib as Adjuvant Therapy for EGFR-Mutated NSCLC

2020 Year in Review - Lung Cancer - Lung Cancer

Neoadjuvant Nivolumab plus Chemotherapy Achieves Promising Responses in Resectable NSCLC (CheckMate-816)

2020 Year in Review - Lung Cancer - Lung Cancer

1
2
3

Page 2 of 3
Results 11 - 20 of 24

To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".

I'd like to receive:

TOP Print Edition

TOP Weekly e‑Newsletter

I have reviewed and consent to the terms of TOP's Privacy Policy, and TOP has my permission to retain my information in its database, and to forward pertinent communications to me.